Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.
NCT05576779
·
clinicaltrials.gov ↗
COMPLETED
Status
2101
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Sclerosis
Interventions
OTHER:
Ofatunumab
Sponsor
Novartis Pharmaceuticals